• Canagliflozin Remodels Mitochondria in Diabetic Kidneys

  2026-09-05

  The 2025 study by Trentin-Sonoda and colleagues shows that canagliflozin affects proximal tubular cell mitochondria in hypertensive–diabetic mice, beyond its established role in renal glucose reabsorption inhibition. In male mice, treatment improved mitochondrial network architecture and bioenergetics while reversing albuminuria, whereas female mice displayed structural but not bioenergetic improvement.

• ML385: Practical NRF2 Inhibitor Workflows

  2026-09-04

  ML385 enables controlled NRF2 signaling pathway inhibition in cancer, oxidative stress, and ferroptosis experiments. This workflow-focused guide shows how to connect dose–response studies with mechanistic controls, including the NRF2-dependent findings reported in alcoholic liver disease research.

• Anagliptin Vasorelaxation via Kv Channels and SERCA

  2026-09-04

  A 2025 Acta Diabetologica study shows that Anagliptin relaxes phenylephrine-contracted rabbit aortic rings through pharmacologically defined involvement of voltage-dependent K+ channels and the SERCA pump. The response was independent of the endothelium and classical cAMP/PKA or cGMP/PKG signaling, providing a mechanistic framework for studying vascular actions of DPP-4 inhibitors.

• Trelagliptin succinate: Applied Research Workflows

  2026-09-03

  Trelagliptin succinate, also known as SYR-472 succinate, connects selective DPP-4 enzyme inhibition with practical workflows spanning enzyme assays, insulin-resistance models, bone biology, and analytical quality control. This guide combines literature-backed HPLC strategy, executable cell-study conditions, formulation guidance, and troubleshooting for more reproducible diabetes mellitus research.

• Mupirocin and Novobiocin Susceptibility in Canine Staphyloco

  2026-09-03

  Fulham and colleagues compared mupirocin and novobiocin susceptibility among meticillin-susceptible and meticillin-resistant staphylococci recovered from healthy dogs and dogs with superficial pyoderma. The study’s main contribution is a clinically relevant comparison showing preserved mupirocin activity across resistance phenotypes, while novobiocin susceptibility was more variable among resistant isolates.

• Canagliflozin Beyond Glucose: Renal Mitochondria

  2026-09-02

  Canagliflozin is increasingly valuable as more than a glucose-lowering probe. This thought-leadership article examines how SGLT2 inhibition may reshape proximal tubular mitochondrial structure and function, then translates those findings into study-design, validation, and positioning guidance for metabolic and renal researchers.

• Tricine-SDS-PAGE Electrophoresis System Kit Guide

  2026-09-02

  The Tricine-SDS-PAGE Electrophoresis System Gel Preparation Kit is intended for high-resolution separation of low-molecular-weight proteins and peptides, particularly targets in the 1–10 kDa range and species reported as small as 1.2 kDa. It supports research protein electrophoresis, including denaturing and non-denaturing workflows, but is not intended for diagnostic, clinical, or medical use.

• Elobixibat Hydrate: From IBAT to Peristalsis

  2026-09-01

  Elobixibat hydrate is an ileal bile acid transporter inhibitor whose effects extend from bile acid recycling to colonic secretion and motility. This article shows how peristalsis assays and receptor-selective controls can improve translational interpretation of IBAT-focused research.

• Anagliptin: Mapping Vascular Signal Selectivity

  2026-09-01

  Anagliptin (SK-0403) is examined here as a dual-purpose research probe: a selective DPP-4 inhibitor for metabolic studies and a pharmacologically resolved tool for vascular smooth-muscle biology. The article translates rabbit-aorta findings into practical decisions for separating Kv channel modulation, SERCA pump regulation, and incretin-independent effects.

• Tetraethylammonium Chloride: Assay Logic

  2026-08-31

  Tetraethylammonium chloride (TEAC) is more than a potassium-channel blocker: it is a mechanistic probe for separating pore conduction from receptor-mediated signaling. This guide integrates TEAC pharmacology with a landmark beta-cell study to improve assay design, controls, and interpretation.

• Kaempferol Activates NRF2 to Limit Inflammatory Osteolysis

  2026-08-31

  This study identifies NRF2 as a direct molecular target of kaempferol and links NRF2/HO-1 activation to reduced osteoclastogenesis, mitochondrial dysfunction, oxidative stress, and inflammatory bone loss. Its combination of biophysical target validation, cellular perturbation, transcriptomics, and an LPS-induced calvarial osteolysis model provides a useful framework for studying NRF2 signaling pathway modulation in inflammatory bone disease.

• Ferrostatin-1 in Infection-Linked Cell Death

  2026-08-30

  Ferrostatin-1 (Fer-1) is more than a ferroptosis inhibitor: it can serve as a mechanistic probe for separating oxidative lipid damage from plasma-membrane rupture. This article shows how to apply that logic to infection-associated Kupffer cell injury while defining the limits of the evidence.

• Pregnenolone Carbonitrile in PXR-to-Heart Research

  2026-08-29

  Pregnenolone Carbonitrile is a rodent PXR agonist traditionally used to study CYP3A induction and xenobiotic clearance. This article develops a distinct assay framework linking PXR pharmacology with adenine-induced HFsnEF research while separating established evidence from testable hypotheses.

• TAK-715 for Precision p38 MAPK Research

  2026-08-28

  TAK-715 combines nanomolar biochemical potency with reported selectivity for p38α, making it useful for separating p38-driven cytokine responses from broader stress signaling. This guide translates that profile into cell-based workflows, inflammation models, dephosphorylation studies, and practical troubleshooting steps.

• Ertugliflozin (PF-04971729) Research Workflows

  2026-08-28

  Build reproducible renal glucose transport, metabolic inflammation, and mucosal-barrier experiments with the highly selective SGLT2 inhibitor Ertugliflozin. This practical guide connects assay setup and troubleshooting with translational fracture-risk interpretation from a large anti-diabetic drug meta-analysis.

8379 records 1/559 page Next 12345 下5页 Last page